{"DataElement":{"publicId":"7587880","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification Reason","preferredDefinition":"Reason for the modification of a dose of agent._An explanation of the cause of some phenomenon or action._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOSE_MOD_RSN","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2008655","version":"2.31","preferredName":"Agent Dose Modification Reason","preferredDefinition":"Reason for the modification of a dose of agent.","longName":"AGT_DOSE_MOD_RSN","context":"SPOREs","contextVersion":"2.31","ObjectClass":{"publicId":"2390594","version":"1","preferredName":"Agent Dose Modification","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The amount of medicine taken, or radiation given, at one time.:Modification; the act of making something different.","longName":"C1708:C25488:C25572","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Modification","conceptCode":"C25572","definition":"Modification; the act of making something different.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE52ECB4-C377-617F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-16","modifiedBy":"ONEDATA","dateModified":"2005-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2390595","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE52ECB4-C378-617F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-16","modifiedBy":"ONEDATA","dateModified":"2005-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99BA9DC8-43C7-4E69-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7587879","version":"1","preferredName":"Agent Modification Reason Inotuzumab Ozogamicin Dose Modification Inotuzumab Ozogamicin","preferredDefinition":"An explanation of the cause of some phenomenon or action._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOS_MOD_RSN","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Hepatic toxicity per protocol","valueDescription":"Hepatic Toxicity","ValueMeaning":{"publicId":"3404793","version":"1","preferredName":"Hepatic Toxicity","longName":"3404793","preferredDefinition":"Refers to the liver.: Toxicity; the degree to which something is poisonous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatic","conceptCode":"C13308","definition":"Pertaining to, affecting, or associated with the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA9519D4-D5E3-734E-E040-BB89AD43494A","latestVersionIndicator":"Yes","beginDate":"2012-03-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2012-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC413414-D579-1246-E053-4EBD850A8E3A","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"Dose limiting toxicity","valueDescription":"Regimen-Limiting Toxicity","ValueMeaning":{"publicId":"7414962","version":"1","preferredName":"Regimen-Limiting Toxicity","longName":"7414962","preferredDefinition":"A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regimen-Limiting Toxicity","conceptCode":"C123282","definition":"A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-345F-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC413414-D58D-1246-E053-4EBD850A8E3A","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7587878","version":"1","preferredName":"Dose Modification Inotuzumab Ozogamicin Reason","preferredDefinition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.:A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.:An explanation of the cause of some phenomenon or action.","longName":"C54346:C71542:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC413414-D54B-1246-E053-4EBD850A8E3A","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC413414-D55C-1246-E053-4EBD850A8E3A","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Reason for dose omission or d","type":"Preferred Question Text","description":"Reason for dose omission or delay (per protocol):","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC443548-ABA3-5C69-E053-4EBD850AE059","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}